Celldex Therapeutics, Inc. (NASDAQ:CLDX) shares passed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $22.14 and traded as high as $27.90. Celldex Therapeutics shares last traded at $27.38, with a volume of 284,359 shares changing hands.
CLDX has been the topic of several recent analyst reports. HC Wainwright boosted their target price on Celldex Therapeutics from $25.00 to $36.00 and gave the stock a “buy” rating in a research report on Monday, March 1st. Cantor Fitzgerald increased their target price on Celldex Therapeutics from $22.00 to $35.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 23rd. Finally, Zacks Investment Research downgraded Celldex Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, April 14th.
The firm has a market capitalization of $1.08 billion, a PE ratio of -12.28 and a beta of 2.96. The business has a 50 day moving average price of $25.23 and a 200-day moving average price of $22.14.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CLDX. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in Celldex Therapeutics in the 1st quarter valued at approximately $51,000. Pacer Advisors Inc. purchased a new position in Celldex Therapeutics in the 4th quarter valued at approximately $64,000. First Mercantile Trust Co. purchased a new position in Celldex Therapeutics in the 1st quarter valued at approximately $72,000. Pinz Capital Management LP purchased a new position in Celldex Therapeutics in the 1st quarter valued at approximately $103,000. Finally, E Fund Management Co. Ltd. purchased a new position in Celldex Therapeutics in the 1st quarter valued at approximately $105,000. 80.15% of the stock is owned by hedge funds and other institutional investors.
Celldex Therapeutics Company Profile (NASDAQ:CLDX)
Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation.
Recommended Story: Why is the Consumer Price Index (CPI) important?
Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.